<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00606138</url>
  </required_header>
  <id_info>
    <org_study_id>06120402</org_study_id>
    <nct_id>NCT00606138</nct_id>
  </id_info>
  <brief_title>Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging</brief_title>
  <official_title>Investigation of Ranibizumab for the Treatment of Persistent Diabetic Neovascularization as Assessed by Super Wide-Field Angiography (Optos)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic neovascularization refers to a type of diabetic retinopathy which is worsening by
      the abnormal growth of blood vessels in the back of the eye, damaging the retina. The usual
      treatment is a type of laser, called panretinal photocoagulation. One drawback is that the
      amount of space within the eye for use of this treatment eventually has its limit, and should
      not be used too near the part of the retina used for detailed vision (the macula). In similar
      eye disorders, there are certain injectable medications called anti-VEGF treatments which can
      slow down or stop this abnormal blood vessel growth. This study sought to compare use of
      ranibizumab versus standard panretinal photocoagulation in treatment of diabetic
      neovascularization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose is to compare the efficacy of ranibizumab versus additional panretinal
      photocoagulation on diabetic neovascularization that is persistent despite previous treatment
      with panretinal photocoagulation. We hypothesize that ranibizumab intravitreal injections
      would induce neovascular regression in similar or better fashion than supplemental laser
      photocoagulation. Consented, enrolled subjects will either receive open-label intravitreal
      injections of 0.5-mg dose of ranibizumab or additional panretinal photocoagulation (up to 500
      300-500 um laser spots) in a ratio of two-to-one (2:1) at the beginning of the study period.
      ETDRS best-corrected visual acuity, contrast sensitivity, and Optos color photography will be
      performed at enrollment, at weeks 1, 2, 3 and 4, and at months 2, 3, 4, 5 and 6. The subjects
      will undergo fluorescein angiography utilizing the Optomap FA (fluorescein angiography)
      system and optical coherence tomography (OCT) at enrollment, at weeks 2 and 4, and at months
      2, 3, 4 and 6. The subjects will be followed for a 6-month period for stabilization,
      regression, or recurrence of neovascularization. In addition, patients will be evaluated for
      occurrence of macular edema.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Mean Percentage Change of the Area of the Patient's Neovascularization as Measured in Pixels by Optomap FA (Fluorescein Angiography)</measure>
    <time_frame>Week 4; Month 6</time_frame>
    <description>This is a measurement of how much change in neovascularization has occurred, using the Optomap FA readings to calculate the increase or decrease in surface area of the retina that is affected by neovascularization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Mean Percentage Change of Macular Edema Measured by Retinal Thickness by OCT (Optical Coherence Tomography)</measure>
    <time_frame>Week 4; Month 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and Severity of Ocular Adverse Events, as Identified by Ophthalmic Examination</measure>
    <time_frame>Month 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and Severity of Other Adverse Events, as Identified by Physical Examination, Subject Reporting, and Changes in Vital Signs</measure>
    <time_frame>Week 1, 2, 4; Month 2, 3, 4, 5, 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Best Corrected Visual Acuity (BCVA), as Assessed by the Number of Letters Read Correctly on the ETDRS Eye Chart at a Starting Test Distance of 4 Meters</measure>
    <time_frame>Week 4; Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Gaining 3 or More Lines of Vision According to ETDRS Eye Chart Testing</measure>
    <time_frame>Week 1, 2, 4; Month 2, 3, 4, 5, 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence Rate of Proliferative Diabetic Complications Including Vitreous Hemorrhage, Iris Neovascularization, and Tractional Retinal Detachment</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Proliferative Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Anti-VEGF injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal injection of 0.5-mg dose of ranibizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRP Laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Additional panretinal photocoagulation (up to 500 300-500 um laser spots)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <description>One 0.5 mg intravitreal injection</description>
    <arm_group_label>Anti-VEGF injection</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laser photocoagulation</intervention_name>
    <description>panretinal photocoagulation (up to 500 300-500 um laser spots)</description>
    <arm_group_label>PRP Laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study

          -  Age 18 years or older

        Patient related considerations:

          -  Patients with Diabetes Mellitus (Type I or II) are eligible. HgA1c will be evaluated
             at the beginning of the study, but this value will have no significance in inclusion
             or exclusion.

          -  Patients will not be pregnant at enrollment and must provide evidence of the use of
             two types of birth control while enrolled in the study.

          -  Patients will have no known sensitivity to ranibizumab or other anti-VEGF injections.

        Disease related considerations:

          -  Patients will have diabetic neovascularization as seen on fluorescein angiography that
             was previously treated with full (at least 1200 laser burns) panretinal
             photocoagulation and that has persisted at least three months.

          -  There will be no evidence of ocular inflammation at enrollment.

          -  There is no restriction on patient's current medications or concomitant illnesses as
             long as there is no interference with patient follow-up.

        Other considerations:

          -  Patients may not be enrolled in another clinical study or observational trial.

          -  There is no limitation on patient's institutional status as long as the patient is
             able to participate in follow-up.

        Exclusion Criteria:

          -  Pregnancy (positive pregnancy test)

          -  Uncontrolled glaucoma on three medicines or more to control intraocular pressure

          -  Prior enrollment in the study

          -  Any other condition that the investigator believes would pose a significant hazard to
             the subject if the investigational therapy were initiated

          -  Participation in another simultaneous medical investigation or trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathew W MacCumber, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2008</study_first_submitted>
  <study_first_submitted_qc>January 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2008</study_first_posted>
  <results_first_submitted>December 7, 2012</results_first_submitted>
  <results_first_submitted_qc>November 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 6, 2014</results_first_posted>
  <last_update_submitted>November 4, 2014</last_update_submitted>
  <last_update_submitted_qc>November 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects will be recruited starting in 2007 and until sufficient subject population is reached. They will be seen in an eye clinic at Rush University Medical Center.</recruitment_details>
      <pre_assignment_details>There is no wash-out period. Recruited subjects must be in need of treatment for their PDR, and will be randomized and treated at the baseline visit.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1 - Ranibizumab</title>
          <description>Intravitreal injection of 0.5-mg dose of ranibizumab</description>
        </group>
        <group group_id="P2">
          <title>2 - Additional PRP Treatment</title>
          <description>Additional panretinal photocoagulation (up to 500 300-500 um laser spots)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 - Ranibizumab</title>
          <description>Intravitreal injection of 0.5-mg dose of ranibizumab</description>
        </group>
        <group group_id="B2">
          <title>2 - Additional PRP Treatment</title>
          <description>Additional panretinal photocoagulation (up to 500 300-500 um laser spots)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="50" upper_limit="62"/>
                    <measurement group_id="B2" value="67" lower_limit="60" upper_limit="73"/>
                    <measurement group_id="B3" value="59" lower_limit="50" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Mean Percentage Change of the Area of the Patient's Neovascularization as Measured in Pixels by Optomap FA (Fluorescein Angiography)</title>
        <description>This is a measurement of how much change in neovascularization has occurred, using the Optomap FA readings to calculate the increase or decrease in surface area of the retina that is affected by neovascularization.</description>
        <time_frame>Week 4; Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 - Ranibizumab</title>
            <description>Intravitreal injection of 0.5-mg dose of ranibizumab</description>
          </group>
          <group group_id="O2">
            <title>2 - Additional PRP Treatment</title>
            <description>Additional panretinal photocoagulation (up to 500 300-500 um laser spots)</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Percentage Change of the Area of the Patient's Neovascularization as Measured in Pixels by Optomap FA (Fluorescein Angiography)</title>
          <description>This is a measurement of how much change in neovascularization has occurred, using the Optomap FA readings to calculate the increase or decrease in surface area of the retina that is affected by neovascularization.</description>
          <units>percentage of change in area (mean)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-84.1">Data can't be calculated due to lack of original case reports</measurement>
                    <measurement group_id="O2" value="52.6">Data can't be calculated due to lack of original case reports</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.8">Data can't be calculated due to lack of original case reports</measurement>
                    <measurement group_id="O2" value="55.4">Data can't be calculated due to lack of original case reports</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Mean Percentage Change of Macular Edema Measured by Retinal Thickness by OCT (Optical Coherence Tomography)</title>
        <time_frame>Week 4; Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 - Ranibizumab</title>
            <description>Intravitreal injection of 0.5-mg dose of ranibizumab</description>
          </group>
          <group group_id="O2">
            <title>2 - Additional PRP Treatment</title>
            <description>Additional panretinal photocoagulation (up to 500 300-500 um laser spots)</description>
          </group>
        </group_list>
        <measure>
          <title>The Mean Percentage Change of Macular Edema Measured by Retinal Thickness by OCT (Optical Coherence Tomography)</title>
          <units>percentage of change (mean)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.2">Data can't be calculated due to lack of original case reports</measurement>
                    <measurement group_id="O2" value="-8.4">Data can't be calculated due to lack of original case reports</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5">Data can't be calculated due to lack of original case reports</measurement>
                    <measurement group_id="O2" value="-2.1">Data can't be calculated due to lack of original case reports</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence and Severity of Ocular Adverse Events, as Identified by Ophthalmic Examination</title>
        <time_frame>Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 - Ranibizumab</title>
            <description>Intravitreal injection of 0.5-mg dose of ranibizumab</description>
          </group>
          <group group_id="O2">
            <title>2 - Additional PRP Treatment</title>
            <description>Additional panretinal photocoagulation (up to 500 300-500 um laser spots)</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence and Severity of Ocular Adverse Events, as Identified by Ophthalmic Examination</title>
          <units>number of events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence and Severity of Other Adverse Events, as Identified by Physical Examination, Subject Reporting, and Changes in Vital Signs</title>
        <time_frame>Week 1, 2, 4; Month 2, 3, 4, 5, 6</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Best Corrected Visual Acuity (BCVA), as Assessed by the Number of Letters Read Correctly on the ETDRS Eye Chart at a Starting Test Distance of 4 Meters</title>
        <time_frame>Week 4; Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 - Ranibizumab</title>
            <description>Intravitreal injection of 0.5-mg dose of ranibizumab</description>
          </group>
          <group group_id="O2">
            <title>2 - Additional PRP Treatment</title>
            <description>Additional panretinal photocoagulation (up to 500 300-500 um laser spots)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Best Corrected Visual Acuity (BCVA), as Assessed by the Number of Letters Read Correctly on the ETDRS Eye Chart at a Starting Test Distance of 4 Meters</title>
          <units>lines of vision gained</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="1"/>
                    <measurement group_id="O2" value="0" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="1.5"/>
                    <measurement group_id="O2" value="2" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Gaining 3 or More Lines of Vision According to ETDRS Eye Chart Testing</title>
        <time_frame>Week 1, 2, 4; Month 2, 3, 4, 5, 6</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence Rate of Proliferative Diabetic Complications Including Vitreous Hemorrhage, Iris Neovascularization, and Tractional Retinal Detachment</title>
        <time_frame>Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 - Ranibizumab</title>
            <description>Intravitreal injection of 0.5-mg dose of ranibizumab</description>
          </group>
          <group group_id="O2">
            <title>2 - Additional PRP Treatment</title>
            <description>Additional panretinal photocoagulation (up to 500 300-500 um laser spots)</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence Rate of Proliferative Diabetic Complications Including Vitreous Hemorrhage, Iris Neovascularization, and Tractional Retinal Detachment</title>
          <units>number of PDR complications</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1 - Ranibizumab</title>
          <description>Intravitreal injection of 0.5-mg dose of ranibizumab</description>
        </group>
        <group group_id="E2">
          <title>2 - Additional PRP Treatment</title>
          <description>Additional panretinal photocoagulation (up to 500 300-500 um laser spots)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye injury, mild, unrelated to treatment</sub_title>
                <description>Subject experienced pain and mild subjconjunctival hemorrhage due to a minor blow to the eye during gardening; unrelated to study participation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mathew MacCumber, MD, PhD</name_or_title>
      <organization>Rush University Medical Center</organization>
      <phone>312-563-4032</phone>
      <email>denise_voskuil-marre@rush.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

